Vivity IOL: Emmetropia Compared to Monovision.

Carolina Eyecare Physicians, LLC (Other)
Overall Status
Active, not recruiting ID
Science in Vision (Other)

Study Details

Study Description

Brief Summary

Current visual outcomes expectations of cataract patients are similar to those of refractive surgery patients. Their desire is to be spectacle independent for far, intermediate and near vision activities. Different options are available including: mono-vision and presbyopia correcting intraocular lenses (IOL). Presbyopia correcting IOLs include accommodative, multifocal, trifocal and extended depth of focus (EDOF) IOLs. The Vivity Extended Vision IOL is not a multifocal IOL but due to its design, it provides better intermediate and near VA compared to a monofocal IOL.

Condition or Disease Intervention/Treatment Phase
  • Device: Vivity IOL

Detailed Description

The study is concerned with the visual performance of the Vivity Extended Vision IOL at distance, intermediate and near when one of the eyes is targeted for emmetropia and the other is targeted for slight myopia. Patients will serve as their own controls with visual performance evaluated against corrected vision with a target of emmetropia in both eyes.

Study Design

Study Type:
Actual Enrollment :
33 participants
Intervention Model:
Crossover Assignment
None (Open Label)
Primary Purpose:
Official Title:
Visual Outcomes, Patient Satisfaction and Spectacle Independence Evaluation of the Acrysof® IQ Vivity® Intraocular Lens Targeted for Emmetropia or Nanovision.
Actual Study Start Date :
Sep 3, 2020
Anticipated Primary Completion Date :
Aug 30, 2022
Anticipated Study Completion Date :
Aug 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Monovision

The target refraction is plano (0.00 D) for the dominant eye and between -0.50 D and -0.75 D for the non-dominant eye. The Vivity IOL will be implanted bilaterally. Corrected vision will involve correcting the dominant eye for emmetropia and the non-dominant eye for -0.50 D.

Device: Vivity IOL
The Vivity IOL will be implanted bilaterally in all subjects.

Active Comparator: Emmetropia

Subject's vision will be tested with both eyes corrected for emmetropia.

Device: Vivity IOL
The Vivity IOL will be implanted bilaterally in all subjects.

Outcome Measures

Primary Outcome Measures

  1. Binocular uncorrected near (40 cm) visual acuity [3 months]

    The logMAR binocular uncorrected visual acuity at 40 cm will be measured.

Eligibility Criteria


Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:

Subjects must fulfill the following conditions to qualify for enrollment into the trial

  1. Subject is undergoing bilateral lens extraction with intraocular lens implantation.

  2. Gender: Males and Females.

  3. Age: 50 years and older.

  4. Willing and able to provide written informed consent for participation in the study

  5. Willing and able to comply with scheduled visits and other study procedures.

  6. Scheduled to undergo standard cataract surgery with topical anesthesia in both eyes within 6 to 30 days between surgeries

  7. Subjects who require an IOL power in the range of +15.0 D to +25.0 D only.

  8. Subjects who require a toric IOL up to +3.00 D at the IOL plane (2.06 D corneal plane).

  9. Potential postoperative visual acuity of 0.2 logMAR (20/32 Snellen) or better in both eyes.

Exclusion Criteria:

Subjects with any of the following conditions on the eligibility exam may not be enrolled into the trial.

  1. Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferative diabetic retinopathy, shallow anterior chamber, macular edema, retinal detachment, aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization, medically uncontrolled glaucoma, microphthalmos or macrophthalmos, optic nerve atrophy, macular degeneration (with anticipated best postoperative visual acuity less than 20/30), advanced glaucomatous damage, etc.

  2. Uncontrolled diabetes.

  3. Use of any systemic or topical drug known to interfere with visual performance.

  4. Contact lens use during the active treatment portion of the trial.

  5. Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.

  6. Clinically significant corneal dystrophy

  7. History of chronic intraocular inflammation.

  8. History of retinal detachment.

  9. Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules.

  10. Previous intraocular surgery.

  11. Previous corneal refractive surgery (i.e. laser-assisted in situ keratomileusis, photorefractive keratectomy, radial keratotomy).

  12. Previous keratoplasty

  13. Severe dry eye

  14. Pupil abnormalities

  15. Anesthesia other than topical anesthesia (i.e. retrobulbar, general, etc).

  16. Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results.

  17. Participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial.

The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates the patient is unsuitable for the trial.

Contacts and Locations


Site City State Country Postal Code
1 Carolina Eyecare Physicians, LLC Mount Pleasant South Carolina United States 29464

Sponsors and Collaborators

  • Carolina Eyecare Physicians, LLC
  • Science in Vision


  • Principal Investigator: Kerry Solomon, Carolina Eyecare Physicians, LLC

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Carolina Eyecare Physicians, LLC Identifier:
Other Study ID Numbers:
  • CEP 20-002
First Posted:
Jul 19, 2022
Last Update Posted:
Jul 21, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Product Manufactured in and Exported from the U.S.:
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 21, 2022